Infinity Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

INFI 1.20 +0.01 (0.84%)
price chart
Why Infinity Pharmaceuticals Inc. Is Being Obliterated Today
So what: Infinity Pharmaceuticals released data from its phase 2 monotherapy study of duvelisib, the company's investigational compound being researched as a possible treatment for non-Hodgkin lymphoma.
Why Infinity Pharmaceuticals Crashed  24/7 Wall St.
Infinity Pharmaceuticals' Disappointing Data  Barron's
Will Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) beat earning estimates again?
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is projected to declare fiscal fourth quarter financial results right after the stock market's official close on February 28, 2017.
Analysts Reviewing Stock: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)  Street Updates
Infinity Pharma cuts 100 jobs after AbbVie deal is terminated
Infinity Pharmaceuticals Inc. said Tuesday it will cut 100 jobs and give retention bonuses to remaining employees - including a total of almost $1 million to four top executives - in a bid to continue developing its experimental treatment for blood ...
AbbVie (ABBV) Exercises Right to End Duvelisib Collaboration with Infinity ...
AbbVie scraps Infinity collab in wake of weak data; biotech slashes jobs  FierceBiotech
Infinity Pharmaceuticals stock plunges toward record low after drug study ...
Shares of Infinity Pharmaceuticals Inc. INFI, +0.84% plummeted 66% in premarket trade Tuesday, toward an all-time low, after the biotechnology company announced a restructuring that would reduce its workforce by 21% in the wake of disappointing ...
Biotech Stocks To Put On Your Watch List: Infinity Pharmaceuticals, Inc ...
Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) added 1.75% by the end of trading session at $1.16. The net percentage change is -86.34% over the last 12 months.
Upcoming Earnings Report: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) gained 0.82% to reach at the trading price of $1.23 as it is set to release its next quarterly earnings report on February 28, 2017.
The Infinity Pharmaceuticals Inc. (INFI) Receives $1.55 Average Price Target ...  DailyQuint
Next Weeks Broker Price Targets For Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)  Fiscal Standard
Infinity Pharmaceuticals Inc. (INFI) Rating Reiterated by JPMorgan Chase & Co.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI)'s stock had its “hold” rating reissued by JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday.
FY2016 Earnings Estimate for Infinity Pharmaceuticals Inc. Issued By William ...  BBNS
Infinity Pharmaceuticals Stock Could Reach $15
Infinity's newest pipeline candidate is an immuno-oncology product in Phase 1 studies, IPI-549, is an oral selective PI3K-gamma inhibitor that targets the tumor microenvironment for solid tumors.
Brokerage Firm Target Review on Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Equity research analysts have provided views on where they believe Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will be trading in the future.
Trade: The FBR & Co Analysts Increase Earnings Estimates for Infinity ...  DailyQuint
Stock Perspective: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Company ...  CSZ News
Analysts Set Infinity Pharmaceuticals Inc. (INFI) Target Price at $1.50
Infinity Pharmaceuticals logo Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has been given an average rating of “Hold” by the ten ratings firms that are covering the firm.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Reviewed By Analysts  The De Soto Edge